Regulatory role of BTLA and HVEM checkpoint inhibitors in T cell activation in a perciform fish Larimichthys crocea.

Dev Comp Immunol

College of Life Sciences, Key Laboratory for Cell and Gene Engineering of Zhejiang Province, Zhejiang University, Hangzhou, People's Republic of China; Laboratory for Marine Biology and Biotechnology, Qingdao National Laboratory for Marine Science and Technology, Qingdao, People's Republic of China. Electronic address:

Published: March 2022

The BTLA and HVEM are two well-characterized immune checkpoint inhibitors in humans and other mammalian species. However, the occurrence and functionality of these two molecules in non-mammalian species remain poorly understood. In the present study, we identified the BTLA and HVEM homologs from large yellow croaker (Larimichthys crocea), an economically important marine species of the perciform fish family. The Larimichthys crocea BTLA and HVEM (LcBTLA and LcHVEM) share conserved structural features to their mammalian counterparts, and they were expressed in various tissues and cells examined at different transcriptional levels, with particular abundance in immune-relevant tissues and splenic leukocytes. Immunofluorescence staining and flow cytometry analysis showed that LcHVEM and LcBTLA proteins were distributed on MHC-II APCs and CD4-2 T cells, and a strong interaction between LcBTLA and LcHVEM was detected in splenic leukocytes in the mixed lymphocyte reaction (MLR). By blockade assays using anti-LcBTLA and anti-LcHVEM Abs as well as recombinant soluble LcBTLA and LcHVEM proteins in different combinations, it was found that LcBTLA-LcHVEM interactions play an important inhibitory role in the activation of alloreactive T cells using MLR as a model, and APC-initiated antigen-specific CD4-2 T cells in response to A. hydrophila (A. h) stimulation. These observations highlight the extensive functional roles of LcBTLA and LcHVEM immune-checkpoint inhibitors in allogeneic T cell reactions, and CD4-2 T cell-mediated adaptive immune responses in Larimichthys crocea. Thus, the BTLA-HVEM checkpoint may represent an ancient coinhibitory pathway, which was originated in fish and was conserved from fish to mammals throughout the vertebrate evolution.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dci.2021.104312DOI Listing

Publication Analysis

Top Keywords

btla hvem
16
larimichthys crocea
16
lcbtla lchvem
16
checkpoint inhibitors
8
perciform fish
8
crocea btla
8
splenic leukocytes
8
cd4-2 cells
8
lcbtla
5
lchvem
5

Similar Publications

BTLA and HVEM: Emerging players in the tumor microenvironment and cancer progression.

Cytokine

October 2023

Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.

Article Synopsis
  • Immunotherapy, especially immune checkpoint inhibitors (ICIs), is changing cancer treatment by targeting proteins that prevent the immune system from attacking cancer cells, with key examples being PD-1, PD-L1, and CTLA-4.
  • Further research has revealed another checkpoint mechanism involving BTLA and HVEM, which are linked to immune regulation and have been found overexpressed in several cancers like lung, ovarian, and glioblastoma.
  • The exploration of the BTLA/HVEM checkpoint is important for advancing immunotherapy options, aiming to enhance cancer treatment outcomes.
View Article and Find Full Text PDF

Immunologic self-tolerance involves signals from co-inhibitory receptors. Several T cell co-inhibitors, including PD-1, are expressed upon activation, whereas CD5 and BTLA are expressed constitutively. The relationship between constitutively expressed co-inhibitors and when they are needed is unknown.

View Article and Find Full Text PDF
Article Synopsis
  • Pulmonary tuberculosis (PTB) is a serious infectious disease, and understanding the immune response to it could aid in developing treatments for drug-resistant cases, particularly by focusing on regulatory T cells (Tregs) which suppress immune responses to the bacteria.
  • The study used flow cytometry to analyze Treg frequency and the expression of key immune molecules (BTLA, HVEM, PD-L1, PD-1) in PTB patients compared to healthy controls, finding an increased presence of Tregs in patients.
  • Interestingly, while BTLA and HVEM levels decreased on Tregs in PTB patients, these changes suggested a complex interaction that may enhance Treg activation, with mechanisms behind this needing further investigation.
View Article and Find Full Text PDF

The Interactions of T Cells with Myeloid-Derived Suppressor Cells in Peripheral Blood Stem Cell Grafts.

Cells

September 2024

Manitoba Blood and Marrow Transplant Program, Departments of Pediatrics and Child Health and Internal Medicine, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.

The interaction of myeloid-derived suppressor cells (MDSCs) with T cells within G-CSF-mobilized peripheral blood stem cell (PBSC) grafts in patients undergoing autologous or allogeneic hematopoietic stem cell transplantation remains to be elucidated. Through studying allo- and auto-PBSC grafts, we observed grafts containing large numbers of T cells and MDSCs with intergraft variability in their percentage and number. T cells from autologous grafts compared to allografts expressed relative higher percentages of inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, TIGIT and BTLA.

View Article and Find Full Text PDF

N-glycan branching is a potent and multifaceted negative regulator of proinflammatory T cell and B cell function. By promoting multivalent galectin-glycoprotein lattice formation at the cell surface, branching regulates clustering and/or endocytosis of the TCR complex (TCR+CD4/CD8), CD45, CD25, BCR, TLR2 and TLR4 to inhibit T cell and B cell activation/proliferation and proinflammatory TH1 and TH17 over TH2 and induced T regulatory cell responses. In addition, branching promotes cell surface retention of the growth inhibitory receptor CTLA-4.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!